Thermo Fisher (TMO) Q4 2024 Earnings Transcript

Thermo Fisher reported Q4 revenue of $11.4 billion, up 5% year over year, with adjusted EPS up 8% to $6.10 and operating margin expanding 50 bps to 23.9%. The company guided 2025 revenue to $43.5 billion-$44.0 billion and adjusted EPS to $23.10-$23.50, implying 3%-4% organic growth despite a 1% pandemic runoff headwind and a 1.5% FX drag. Management also highlighted $4.6 billion returned to shareholders in 2024, the completed $3.1 billion Olink acquisition, and strong product innovation across instruments and life sciences.

Analysis

TMO is signaling a cyclical inflection that is more important for 2026 than 2025: the combination of stabilizing core demand, a normalized phasing of pandemic runoff, and a step-up in instrument orders suggests the company is exiting the reset phase with leverage intact. The key second-order effect is that revenue recovery is no longer the only story; with cost actions already taken, incremental growth should now convert disproportionately into EPS, which supports the market’s willingness to re-rate quality life-science tools despite only mid-single-digit top-line growth.

The most underappreciated winner is TMO’s services stack, where bundled development/manufacturing capabilities can become a switching-cost moat rather than just a cross-sell. If customers start preferring integrated development workflows to reduce cycle time, smaller CRO/CDMOs and narrower point-solution vendors are structurally disadvantaged, especially if capital markets stay selective and pharma customers concentrate spend with vendors that can de-risk execution.

The contrarian risk is that 2025 guidance may be too conservative on organic growth but not conservative enough on mix and policy friction. FX is an obvious drag, but the bigger latent issue is that academic/government and China stimulus are being treated as stabilizers rather than accelerants; if either disappoints, the market could question the durability of the margin expansion thesis because the company is relying on operating leverage, not pricing, to bridge EPS. Conversely, if instrument order flow and pharma services authorizations persist into Q2/Q3, the setup becomes a positive revision story into 2026.

The stock is likely to trade on whether investors believe 3%-4% organic growth is a trough-ish run-rate rather than a ceiling. The market may be missing that TMO’s real option value is in the long-cycle service pipeline: today’s authorizations can still turn into 2026-2027 revenue, so the current guide likely understates forward earnings power if biotech funding and pharma R&D budgets continue to thaw.

Key Decisions for Investors

• Long TMO on a 3-6 month horizon into the next two quarters of bookings/order conversion; use any post-earnings weakness as entry, targeting a rerate if organic growth inflects and margins hold near the guided 90 bps expansion.
• Pair trade: long TMO / short a basket of narrower tools names with higher China and academic funding sensitivity (e.g., ILMN, BRKR, KEYS) for a 6-9 month relative-value expression; thesis is TMO’s diversified demand base and services leverage should outperform if policy noise persists.
• Buy TMO Jan-2026 $600 calls or call spreads on pullbacks; risk/reward favors upside capture if 2025 serves as the setup year for stronger 2026 growth, with limited downside versus outright equity in a policy-uncertain tape.
• Short-dated hedge: if you are long TMO, buy 3-4 month puts against the position around any rally above near-term resistance; the main risk is a disappointing Q1 print from pandemic runoff phasing or FX, which can create a temporary valuation reset.
• Monitor TMO vs. BDX/STE as a quality healthcare tool pair; if academic/government or diagnostics funding weakens, rotate toward the less policy-sensitive names, but if instrument orders continue to improve, TMO should be the preferred long within the group.